Eribulin mesylate e7389 mesylate, a synthetic analogue of halichondrin b in phase iii clinical trials for breast cancer, binds to tubulin and microtubules. Eribulin mesylate, a nontaxane microtubule dynamics inhibitor, is isolated from the sea sponge halichondria okadai. It has a mean volume of distribution of 43 to 114 lm2 and human plasma protein binding ranges from 49 to 65%. Phase ii study of the halichondrin b analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. Eribulin mesylate is a chemotherapeutic medicine approved to treat metastatic breast cancer, an advanced form of breast cancer that has spread to other parts of the body microtubules are dynamic. Halaven eribulin mesylate injection is a nontaxane microtubule dynamics inhibitor. The recommended dose of halaven eribulin mesylate for liposarcoma is 1. Nct00337103 compared eribulin with capecitabine in patients with locally. Eribulin is an anticancer drug marketed by eisai co. Eribulin mesylate is a synthetic analogue of halichondrin b, a product isolated from the marine sponge, halichondria okadai. Eribulin inhibits the formation of mitotic spindles and blocks cell cycle progression at the g. Eribulin mesylate is a synthetic analogue of halichondrin b. Research and development of halaveneribulin mesylate.
Healthrelated quality of life in patients with locally. Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic. Eribulin mesylate is a synthetic analogue of halichondrin b, a product isolated from the marine sponge halichondria okadai. The mesylate salt of a synthetic analogue of halichondrin b, a substance derived from a marine sponge lissodendoryx sp. Side effects of halaven injection eribulin mesylate. Eribulin mesylate eribulin is an anticancer agent used in patients. All trials on the list are supported by nci ncis basic information about clinical trials. Updated analysis of phase ibii study of eribulin and. Clinical trials using eribulin mesylate national cancer.
Halaven eribulin mesylate dose, indications, adverse. Eribulin mesylate is a structurally simplified synthetic analog of. Pdf this phase iii randomized trial clinicaltrials. Eribulin mesylate in the treatment of metastatic breast cancer ncbi. Eribulin mesylate combined with local treatment for brain metastasis from breast cancer. Despite many available chemotherapeutic options, guidelines do not exist on how best to sequence or combine them. Eribulin is a nontaxane microtubule dynamics inhibitor, belonging to a new class of antineoplastic agents, the halichondrin class. Pharmacokinetics of eribulin mesylate in patients with. A phase 1b2, openlabel, doseescalation, and doseconfirmation. Eribulin mesylate in treating patients with recurrent or. Neoadjuvant eribulin mesylate following anthracycline and taxane in. Eribulin mesylate combined with local treatment for brain.
Halaven eribulin mesylate injection, for intravenous use initial u. Eribulin inhibits the formation of mitotic spindles and blocks cell cycle. Halaventm eribulin mesylate page 1 of 29 product monograph prhalaventm eribulin mesylate injection 0. Eribulin mesylate is a synthetic analogue of halichondrin b, a product isolated from the marine sponge halichondria. For medicaid members, when state medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state medicaid coverage. Pdf malignant adenomyoepithelioma of the breast and. Eribulin for the treatment of metastatic breast cancer. Fungal laccases are well investigated enzymes with high potential in different applications like bleaching of waste materials waters and textiles, cellulose delignification, and organic synthesis. Eribulin injection is used to treat breast cancer that has spread to other parts of the body and that has already been treated with certain other chemotherapy medications. Eribulin mesylate targets human telomerase reverse. Two case reports kyungdo byun, sung gwe ahn, 1 hyung joo baik, anbok lee, ki beom bae, min sung an, kwang hee kim, jae ho shin, ha kyoung park, heunglae cho, 2 joon jeong, 1 and tae hyun kim. Effects of combining eribulin mesylate with carboplatin in four nonsmall cell lung cancer cell lines varied from additive to moderately.
Halaven, eribulin eribulin is the first in the halichondrin class of microtubule dynamics inhibitors with a novel mechanism of action. Eribulin mesylate eribulin is an anticancer agent used in patients with. Eribulin mesylate halaven, approved in 2010 as an anticancer agent. Eribulin mesylate eribulin is a synthetic analogue of the marinesponge.
Perspectives on the mechanism of action and clinical application of. The clinical trials on this list are studying eribulin mesylate. Research paper eribulin mesylate in pretreated breast. Eribulin mesylate for the treatment of the following is considered medically necessary if the medical appropriateness criteria are met. In a clinical study of more than 750 women, halaven was compared with other chemotherapies or hormone therapies commonly used to treat metastatic breast cancer mbc. We achieved the total synthesis using a highly convergent approach joining. Halaven eribulin mesylate, e7389 is a novel anticancer agent discovered and developed by eisai, which was approved by the united states food and drug administration fda for the treatment of. Peripheral neuropathy is a common doselimiting adverse effect of microtubule inhibitors, including eribulin. Eribulin mesilate eribulin is a novel microtubule dynamics inhibitor with mechanisms of action distinct from that of other conventional tubulin.
Eribulin mesylate for treatment of metastatic breast cancer. Eribulin is also known as e7389 and er086526, and also carries the us nci designation nsc707389. If this drug is used during pregnancy, or if a patient becomes pregnant while taking. Clinical trials are research studies that involve people. Breast cancer that has metastasized spread to other parts of the body. Eribulin mesylate e7389 is a nontaxane microtubule dynamics inhibitor, and a structurally simplified synthetic analog of the natural marine product, halichondrin b, with a novel mechanism of. Eribulin mesylate bluecross blueshield of tennessee. Eribulin mesylate in treating patients with recurrent or refractory osteosarcoma the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Structurally eribulin is a simplified and synthetically produced version of halichondrin b, a natural product isolated from the marine sponge halichondria okadai. Pdf phase iii openlabel randomized study of eribulin mesylate.
Eribulin mesylate uses, dmf, dossier, manufacturer. Safety and efficacy study of eribulin in combination with. Eribulin mesylate is a structurally simplified synthetic analogue of halichondrin b a natural product isolated from the marine sponge halichondria okadai. It is used in patients who have already been treated with at least 2 types of chemotherapy for.
26 8 1175 1615 864 1284 438 627 1327 1442 272 15 1343 1590 1293 1269 38 1299 1352 472 1006 1442 1554 1534 828 1085 1478 391 666 641 216 728 644 1027